Product logins

Find logins to all Clarivate products below.


Methicillin-Resistant Staphylococcus Aureus Infections – Epidemiology – Middle East & Africa Data

Methicillin-Resistant Staphylococcus aureus Epidemiology

DRG Epidemiology’s coverage of methicillin-resistant staphylococcus aureus comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of methicillin-resistant staphylococcus aureus for each country, as well as annualized case counts projected to the national population.

DRG Epidemiology’s methicillin-resistant staphylococcus aureus forecast will answer the following questions:

How will changes in the levels of exposure to known risk or protective factors affect the number of methicillin-resistant staphylococcus aureus events per year?

Of all people diagnosed with methicillin-resistant staphylococcus aureus, how many in each country across the major mature pharmaceutical markets are drug-treated?

How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of methicillin-resistant staphylococcus aureus over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following methicillin-resistant staphylococcus aureus patient populations:

Diagnosed MRSA Events by Treatment

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – BSI

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – cIAI

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – cSSSI

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – HAP

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – HCAP

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – Nosocomial Pneumonia

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – SSI

… and more (details available on request).

Note: coverage may vary by country and region.

Related Market Assessment Reports

Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used in parallel to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via…
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…